ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,796.00
0.34%
S&P ASX All Technology
3,092.40
0.70%
Brent Oil
84.435
-0.67%
US Dollar vs AUD
1.50535
0.29%
Bitcoin
64,271.85
-0.85%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) News

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARDS
DateTimeSourceHeadlineSymbolCompany
14/02/202412:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
16/01/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
16/12/202308:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
04/11/202308:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
04/11/202307:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202321:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
14/09/202311:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
08/09/202306:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
26/08/202306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
05/08/202306:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
05/08/202306:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
04/08/202306:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202322:17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202314:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
21/07/202320:49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
21/07/202307:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
18/07/202306:05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
18/07/202305:01Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202321:36Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
12/07/202322:00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
23/06/202320:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
20/06/202322:00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
16/06/202307:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
16/06/202307:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
16/06/202307:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
16/06/202307:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202320:13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202320:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202306:05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
31/05/202322:00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS

Your Recent History

CSE
FRG
Forge Resources
TG
ICNT
Invesco Markets II
EU
9409T
9409T
BOV
PETRF350
PETRF350 Ex:31,26
USOTC
AVHI
Achari Ventures Holdings... (PK)
NASDAQ
SPWH
Sportsmans Warehouse
HUOB
RAIBTC
Rai.Finance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved